#1
#1 out of 1100.00%
health3h ago
New drug approach offers hope for patients with recurrent aggressive cancers
- Merck's sac-TMT showed statistically significant improvements in overall and progression-free survival in recurrent endometrial cancer during a global Phase 3 trial.
- Trial involved 776 patients who had progressed after platinum chemotherapy and immunotherapy and were then randomized to sac-TMT or physician's choice.
- Experts say sac-TMT may address an unmet need for patients with recurrent endometrial cancer, a cancer type on the rise worldwide.
- Sac-TMT is an ADC delivering the drug to tumor cells, aiming to minimize damage to healthy tissue.
- The drug is administered every two weeks via IV infusion in the studied setting.
- Researchers indicated that the results may help meet the needs of patients with recurrent disease after standard therapies.
- Dr. Brian Slomovitz emphasized the potential impact on a cancer type with rising deaths in the United States.
- Investigation into endometrial cancer therapies continues as researchers weigh efficacy and safety in broader populations.
- Merck released a press update framing sac-TMT as potentially addressing an unmet need for advanced endometrial cancer patients.
Vote 0